



Company Overview

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including tamibarotene (formerly SY-1425), a first-in-class oral selective RAR α agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia, and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)

Oct 13 2021, 4:01 PM EDT

Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer

Oct 12 2021, 8:00 AM EDT

Stock Overview

Symbol	SYRS
Exchange	Nasdaq
Market Cap	261.35m
Last Price	\$4.22
52-Week Range	\$4.00 - \$15.6499

10/22/2021 04:00 PM EDT

Investor Relations

Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com

Management Team

Nancy Simonian, M.D.

President and Chief Executive Officer

Conley Chee

Chief Commercial Officer

Jason Haas

Chief Financial Officer

Eric R. Olson, Ph.D.

Chief Scientific Officer

Gerald E. Quirk

Chief Operations Officer

David A. Roth, M.D.

Chief Medical Officer

Kristin Stephens

Chief Development Officer

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive
4th Floor
Cambridge, MA 02140

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.